Fagmiljøer og eksperter over hele verden frykter at vaksinene kan føre til økt risiko for å utvikle kroniske sykdommer, betennelse på hjertet, blodpropper, kreft samt redusert fruktbarhet og sterilitet. I tillegg er det stor bekymring for den såkalte ADE-effekten (Antibody-Dependent Enhancement); antistoffavhengig forsterking som kan føre til en overdreven og potensielt farlig immunrespons ved et nytt møte med et virus. Disse advarslene blir nå utsatt for en omfattende sensur, og når ikke ut i mediene.
Vi har forsøkt å formidle til våre politikere at det er svært mange uavklarte spørsmål ved denne teknologien og at det er ekstremt uansvarlig å implementere bruken av disse vaksinen før vi har langt større innsikt i de biologiske konsekvensene.
En sterk bekymring handler om farene for ADE (Antibody Dependent Enhancement), et fenomen som har gjort at alle tidligere dyreforsøk med å lage vaksiner mot SARS-viruset der forsøksdyrene så ut til å tåle vaksinen greit, men når de i etterkant ble eksponert for viruset de var vaksinert mot utviklet de massesykdom og død.
In studies of an experimental SARS vaccine reported in 2004, vaccinated ferrets (experimental animals) developed harmful inflammation in the liver after being infected with the virus. Their conclusion was that those vaccines induce potent neutralizing and protective responses in immunized animals but may induce antibodies that enhance infection by early human SARS-CoV and animal SARS-CoV–like viruses .
On July 13, 2020, a more comprehensive article was published in Nature in which the authors write:
“Antibody-dependent enhancement (ADE) of disease course is a general concern because the mechanisms underlying antibody protection against viruses have a theoretical potential to amplify the infection or trigger harmful immunopathology after vaccination.”
On September 13, 2020, a third article was published in Nature Microbiology entitled: Antibody Dependent Enhancement and SARS-CoV-2 Vaccines and Therapies.
After a comprehensive review of the issue, the authors conclude with the following statement –
“ADE has been observed in SARS, MERS and other human respiratory viral infections, indicating a real risk of ADE for SARS-CoV-2 vaccines and antibody-based interventions. However, clinical data have not yet been able to fully establish a role for ADE in human COVID-19 pathology »
The authors go on o state that:
“In the future, it will be crucial to evaluate animal and clinical data sets for signs of ADE, and to balance ADE-related safety risk against intervention effects if clinical ADE is observed. Ongoing clinical studies in animals and humans will provide important insights into the mechanisms of ADE in COVID-19. »
As far as we know, no animal studies have been performed with Pfizer, Moderna, AstraZenca or the other vaccines. The Phase III clinical trials conducted with «Warp Speed» have not been able to provide a basis for about the possible risks of developing ADE.
So – over time – if the vaccinated are exposed to SARS-Cov2 or possible other corona viruses, what is the probability that their will be an increased risk in vaccinated groups for serious side effects and deaths that can occur after 3 months, 6 months or even one year after receiving the vaccine? Ad the clinic, trikal.s have become open label studies the clinical trials are not designed to be able to document these possible clinical outcomes.
According to a recent article in the Journal of Infection “Current Covid-19 vaccines (either mRNA or viral vectors) are based on the original Wuhan spike sequence. In as much as neutralizing antibodies overwhelm facilitating antibodies, ADE is not a concern. However, the emergence of SARS-CoV-2 variants may tip the scales in favor of infection enhancement. Our structural and modeling data suggest that it might be indeed the case for Delta variants”.
«Even before the Covid-19 vaccines were on the market, scientists warned of a possible danger of Antibody Dependent Enhancement (ADE), a well-known phenomenon observed in the development of previous coronavirus vaccines. This means that the body produces antibodies, but is unable to neutralize the virus, so by binding to antibodies present on the cell, the virus can enter the cell and multiply more easily.
In a study on vaccine breakthrough cases from the San Francisco Bay area California breakthrough infections were found to be associated with low or undetectable neutralizing antibody levels attributable to immunocompromised state or infection by an antibody resistant lineage. This is seen by several scientists as a possible explanation for the observed reinfections after vaccination. Research from the Mayo Clinic and Boston University shows that six months after the second injection of the Pfizer vaccine the effectiveness decreased from 76% to 42% and with Moderna from 86% to 76%.»